Search

Your search keyword '"Izycka-Swieszewska, E."' showing total 3 results
Start Over Author "Izycka-Swieszewska, E." Topic immunohistochemistry
3 results on '"Izycka-Swieszewska, E."'

1. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.

Author

Gabrych A, Pęksa R, Kunc M, Krawczyk M, Izycka-Swieszewska E, Biernat W, and Bień E

Subjects
Adolescent, Age of Onset, Antibody Specificity, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Neoplasm Staging, Predictive Value of Tests, Progression-Free Survival, Rhabdomyosarcoma mortality, Rhabdomyosarcoma pathology, Rhabdomyosarcoma therapy, Time Factors, B7-H1 Antigen analysis, Biomarkers, Tumor analysis, Immunohistochemistry, Programmed Cell Death 1 Receptor analysis, Rhabdomyosarcoma immunology
Abstract

Background: Activation of immune checkpoints, e.g. PD-1/PD-L1 axis, in cancer microenvironment, enables evasion of host anti-cancer immune response and drives tumor progression. To date, there have been only a few studies analyzing PD-1/PD-L1 expression in pediatric malignancies., Aim: In the current study, we aimed to assess PD-L1 and PD-1 expression in pediatric rhabdomyosarcoma (RMS) and to investigate their clinicopathological associations., Materials and Methods: The study enrolled 31 children with RMS. Tissue microarrays with representative tumor tissue samples were stained with anti-PD-1 NAT105 clone (Ventana, Roche) and two different antibodies against PD-L1: SP142 (Ventana, Roche) and 22C3 (DAKO). Adequate positive controls were applied. Their expression was assessed in tumor-associated immune cells (TAICs) and in the tumor cells separately., Results: We did not detect any positive PD-L1 staining in analyzed tumors using SP142 antibody; however, in 11 cases (35.48%) its expression was revealed by means of 22C3 clone. The staining was restricted to TAICs in all cases, which no reaction in tumor cells. The 5-year relapse free survival (RFS) rate was significantly higher in PD-L1 positive cases (61.5% vs 25.0%, p = 0.024), but it most likely results from more frequent PD-L1 expression in low-stage RMS. PD-1 expression on TAICs was detected in 7 cases and did not influence the prognosis., Conclusions: We found that PD-L1 expression on TAICs, as detected with the use of 22C3 clone but not SP142 antibody, tends to be associated with low-stage RMS in children. PD-1 expression on TAICs in RMS is neither associated with distinct clinical course nor with clinicopathological features., (Copyright © 2019 The Authors. Published by Elsevier GmbH.. All rights reserved.)

Published
2019
Full Text
View/download PDF

2. Meningioangiomatosis with a predominant fibrocalcifying component.

Author

Izycka-Swieszewska, E., Rzepko, R., Kopczynski, S., Franc, Z., Szurowska, E., and Borowska-Lehman, J.

Subjects
*MENINGIOMA, *ANGIOMATOSIS, *PARIETAL lobe, *DISEASES
Abstract

A case of meningioangiomatosis, resected from the parietal lobe in a 31-year-old female is presented. Macroscopically, the lesion was composed of five calcified nodules embedded within hardened elastic tissue. Histologically, cortical and subcortical calcified masses were found surrounded by a palisade of spindle and/or oval cells. In adjacent nervous tissue many pathological microvessels were observed and some were ensheathed by a perivascular proliferation of spindle cells. Moreover, gliosis with Rosenthal fibers and prominent connective tissue elements were observed. Immunohistochemical analysis based on monoclonal antibodies was performed. The spindle cells both within the palisades and the perivascular proliferations were vimentin and usually epithelial membrane antigenpositive. The possible pathogenesis of meningioangiomatosis is discussed and the role of angiogenesis within this lesion emphasized. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

3. COLONIC ADENOCARCINOMAS HARBORING NTRK FUSION GENES: A CLINICOPATHOLOGIC AND MOLECULAR GENETIC STUDY OF 16 CASES AND REVIEW OF THE LITERATURE

Author

Paweł Kita, Sebastian Goertz, Leszek Teresiński, Janusz Ryś, Małgorzata Kołos, Maciej Kaczorowski, Massimo Milione, Krzysztof Okoń, Caj Haglund, Wojciech Biernat, Michal Pyzlak, Anna Guttmejer-Nasierowska, Arndt Hartmann, Artur Kowalik, Małgorzata Chłopek, Shingo Inaguma, Joanna Szpor, Agnieszka Hałoń, Giovanni Centonze, Jarosław Wejman, Magdalena Dubova, Ondrej Daum, Michal Michal, Jennifer Lamoureux, Justyna Szumiło, Abbas Agaimy, Blazej Szostak, Jerzy Lasota, Jason Christiansen, Ewa Chmielik, Ireneusz Dziuba, Rafał Pęksa, Ari Ristimäki, Piotr Waloszczyk, Anna Felisiak-Goląbek, Ewa Iżycka-Świeszewska, Bartosz Wasąg, Markku Miettinen, Stanisław Góźdź, Vincenzo Canzonieri, Wojciech Wesołowski, Janusz Kopczyński, Lasota, J., Chlopek, M., Lamoureux, J., Christiansen, J., Kowalik, A., Wasag, B., Felisiak-Golabek, A., Agaimy, A., Biernat, W., Canzonieri, V., Centonze, G., Chmielik, E., Daum, O., Dubova, M., Dziuba, I., Goertz, S., Gozdz, S., Guttmejer-Nasierowska, A., Haglund, C., Halon, A., Hartmann, A., Inaguma, S., Izycka-Swieszewska, E., Kaczorowski, M., Kita, P., Kolos, M., Kopczynski, J., Michal, M., Milione, M., Okon, K., Peksa, R., Pyzlak, M., Ristimaki, A., Rys, J., Szostak, B., Szpor, J., Szumilo, J., Teresinski, L., Waloszczyk, P., Wejman, J., Wesolowski, W., and Miettinen, M.

Subjects
0301 basic medicine, Male, Oncogene Proteins, Fusion, Colorectal cancer, NTRK1, Fusion gene, 0302 clinical medicine, hemic and lymphatic diseases, 80 and over, Anaplastic lymphoma kinase, fusion genes, Oncogene Proteins, Aged, 80 and over, Colonic Neoplasm, Tumor, Membrane Glycoproteins, biology, Middle Aged, Immunohistochemistry, 3. Good health, Receptor Protein-Tyrosine Kinase, Gene Expression Regulation, Neoplastic, fusion gene, 030220 oncology & carcinogenesis, trkA, trkB, Colonic Neoplasms, trkC, Female, Membrane Glycoprotein, Anatomy, 2 and 3, Human, Receptor, Adenocarcinoma, Article, Pathology and Forensic Medicine, Follow-Up Studie, 03 medical and health sciences, colorectal carcinoma, medicine, Carcinoma, Biomarkers, Tumor, PTEN, Humans, Receptor, trkB, Oncogene Fusion, Receptor, trkC, Receptor, trkA, Fusion, immunohistochemistry, next-generation sequencing, NTRK1, 2 and 3, TRK expression, Aged, Follow-Up Studies, Neoplasm Staging, Receptor Protein-Tyrosine Kinases, Neoplastic, Microsatellite instability, Gene rearrangement, medicine.disease, 030104 developmental biology, Gene Expression Regulation, Cancer research, biology.protein, Surgery, Biomarkers
Abstract

This study determined the frequency and the clinicopathologic and genetic features of colorectal carcinomas driven by oncogenic fusions of the anaplastic lymphoma kinase gene (ALK). Of the 8150 screened tumors, 12 (0.15%) were immunohistochemically ALK-positive with D5F3 antibody. These cancers harbored CAD-ALK (n=1), DIAPH2-ALK (n=2), EML4-ALK (n=2), LOC101929227-ALK (n=1), SLMAP-ALK (n=1), SPTBN1-ALK (n=4), and STRN-ALK (n=1) fusions, as detected by an RNA-based next-generation sequencing assay. ALK fusion carcinomas were diagnosed mostly in older patients with a 9:3 female predominance (median age: 72 y). All tumors, except a rectal one, occurred in the right colon. Most tumors were stage T3 (n=7) or T4 (n=3). Local lymph node and distant metastases were seen at presentation in 9 and 2 patients. These tumors showed moderate (n=6) or poor (n=3) glandular differentiation, solid medullary growth pattern (n=2), and pure mucinous morphology (n=1). DNA mismatch repair-deficient phenotype was identified in 10 cases. Tumor-infiltrating lymphocytes were prominent in 9 carcinomas. In 4 carcinomas, tumor cells showed strong, focal (n=3), or diffuse programmed death-ligand 1 immunoreactivity. CDX2 expression and loss of CK20 and MUC2 expression were frequent. CK7 was expressed in 5 tumors. Four patients died of disease within 3 years, and 7 were alive with follow-up ranging from 1 to 8 years. No mutations in BRAF, RAS, and in genes encoding components of PI3K-AKT/MTOR pathway were identified. However, 1 tumor had a loss-of-function PTEN mutation. Aberration of p53 signaling, TP53 mutations, and/or nuclear accumulation of p53 protein was seen in 9 cases. ALK fusion colorectal carcinomas are a distinct and rare subtype of colorectal cancers displaying some features of mismatch repair-deficient tumors.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results